**Table 5** ALPPS cases in NET patients

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Variable | 1 | 2 | 3 | 4 | 5 | 6 | 7–27 | 28–29 | 30 | 31–38 | 39 | 40 | 41 |
| Author | Alvarez | Alvarez | Alvarez | Ji | Jiao | Kawaguchi | Linecker | Petrowsky | Qu | Schadde | Stavrou | Uribe | Vicente |
| Ref | (32) | (32) | (32) | (33) | (34) | (35) | (36) | (27) | (37) | (22) | (28) | (38) | (39) |
| Year | 2015 | 2015 | 2015 | 2018 | 2019 | 2016 | 2019 | 2015 | 2018 | 2014 | 2017 | 2018 | 2015 |
| Affiliation | Buenos Aires | Buenos Aires | Buenos Aires | Shenzhen | London | Chiba | ALPPS Registry | Zurich | Qingdao City | ALPPS Registry | Hamburg | Santiago | Madrid |
| Country | Argentina | Argentina | Argentina | China | UK | Japan | International | Switzerland | China | International | Germany | Chile | Spain |
| Study period | Jun 2011-Apr 2014 | Jun 2011–Apr 2015 | Jun 2011–Apr 2016 | 2018 | Jul 2015–Oct 2017 | Apr 2013–Sep 2014 | 2010–2017 | Oct 2012–Jun 2014 | 2018 | 2010–2013 | Mar 2015–Mar 2017 | 2013–2015 | Jan 2011–Oct 2014 |
| N | 1 | 1 | 1 | 1 | 1 | 1 | 21 | 2 | 1 | 8 | 1 | 1 | 1 |
| Age (yrs) | 69 | 56 | – | 37 | – | – | 54 (40-60) | – | 72 | – | – | – | 54 |
| Sex (M:F) | F | F | – | M | – | – | 8M–13F | – | F | – | – | – | – |
| Origin  | – | – | – | Pancreas | Pancreas | – | Small bowel 9; Pancreas 7; Duodenum 1; Lung 1; Unknown 2; Ovary 1 | – | Primary hepatic | – | Metastasis | Metastasis | Intestinal metastasis |
| Tumor size | – | – | – | – | – | – | 3.6 (1.9-7.5) | – | 13x7x6 | – | – | – | – |
| Number of lesions | – | – | – | 6 | – | – | 8 (4-12) | – | 1 | – | – | Multiple | – |
| Primary lesion location | – | – | – | SI–II–III–IVa–IVb–V–VIII | – | – | bilobar=20 | – | Right lobe + S4 | – | – | Bilobar | – |
| Neoadjuvant treatment | No | Plakitaxel + gemcitabine | – | No | – | – | LRT=8; CHT=7; PRRT=1; Somatostatin analogues=10 | – | No | – | – | Distal pancreat + spleen and 90Y–DOTATOC + 177Lu–DOTATATE | No |
| Type of liver resection | Right hepatectomy | Right trisectionectomy | – | Left trisectionectomy + DP | RALPPS | – | Right hepatectomy=11; right trisectionectomy=10 | – | Right trisectionectomy | – | – | – | Right trisectionectomy |
| MILS | No | No | – | No | Yes  | – | 1 case | – | 1st stage | – | – | – | No |
| Days, 1-2 stage | – | – | – | 10 | – | – | 11 (8-21) | – | – | – | – | – | 14 |
| FLR pre-1 | 465 mL | 265 mL | – | FLR–ESLV 24% | – | – | – | – | 18% | – | – | – | – |
| FLR pre-2 | 565 mL | 468 mL | – | FLR–ESLV 38% | – | – | – | – | 31% | – | – | – | – |
| FLR hypertrophy | 22% | 77% | – | 58% | – | – | 67 (46-103) | – | 72% | – | – | – | 40% |
| CD post-2 | 3B | 3B | 5 | – | – | – | ≥IIIb=6 | – | 0 | – | – | 0 | II |
| LOS post-2 | 54 | 27 | 62 | – | – | – | 12 (7-16) | – | – | – | – | – | 21 |
| 30-day mortality | – | – | – | – | – | – | No | – | No | – | – | No | – |
| Adjouvant treatment | – | – | – | No | – | – | – | – | 5-FU | – | – | – | – |
| Overall survival | – | – | Death (MOF day 62) | Alive 4 years | – | – | 3 deaths (1, 24 and 62 months), 1-yr OS 95% | – | Alive (1 year) | 0–8 deaths <90 days; 1-yr OS 73% | – | Alive (25 months) | – |
| Recurrence | No | No | No | No | – | – | 12 cases, 1-yr DFS 73% | – | No | 1-yr DFS 83%  | – | No | – |

N, number; M, male; F, female; S, segment; MILS, mini-invasive liver surgery; FLR, future liver remnant; CD, Clavien-Dindo; LOS, length of stay; MOF, multi-organ failure; DP, Duodeno-pancreatectomy; RALPPS, radiofrequency-assisted liver partition and portal vein ligation for staged hepatectomy; DFS, disease-free survival.